Literature DB >> 15655368

Dok1 and SHIP act as negative regulators of v-Abl-induced pre-B cell transformation, proliferation and Ras/Erk activation.

Shinji Oki1, André Limnander, Pin Mei Yao, Masaru Niki, Pier Paolo Pandolfi, Paul B Rothman.   

Abstract

The v-Abl tyrosine kinase activates several signaling pathways during transformation of bone marrow cells in mice. Because the SH2-containing inositol 5'-phosphatase (SHIP) and Downstream of tyrosine kinase 1 (Dok1) have been shown to interact with Abl, the effect of SHIP and Dok1 deficiency on v-Abl transformation was investigated. Bone marrow cells from either Dok1- or SHIP-deficient mice are more susceptible to transformation by v-Abl. v-Abl-transformed preB cells from these knockout mice show Abl kinase-dependent hyperproliferation and moderate resistance to apoptosis. Elevated activation of Ras, Raf-1, and Erk, but not of Akt, was observed in either SHIP(-/-) or Dok1(-/-) v-Abl-transformed cells. This activation is sensitive to treatment with STI571. Furthermore, treatment of these cells with either a farnesyltransferase inhibitor or a MEK1/2 inhibitor abrogates the increased proliferation of SHIP(-/-) or Dok1(-/-) cells in a dose-dependent manner. Complementation of SHIP(-/-) or Dok1(-/-) cells abrogates their hyperproliferation and intracellular Erk activation. These data indicate that both SHIP and Dok1 functionally regulate the activation of Ras-Erk pathway by v-Abl and affect the mitogenic activity of v-Abl transformed bone marrow cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15655368

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  8 in total

1.  Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib.

Authors:  Davorka Messmer; Jessie-F Fecteau; Morgan O'Hayre; Ila S Bharati; Tracy M Handel; Thomas J Kipps
Journal:  Blood       Date:  2010-11-15       Impact factor: 22.113

2.  Dok-1 independently attenuates Ras/mitogen-activated protein kinase and Src/c-myc pathways to inhibit platelet-derived growth factor-induced mitogenesis.

Authors:  Mingming Zhao; Justyna A Janas; Masaru Niki; Pier Paolo Pandolfi; Linda Van Aelst
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

3.  Oncogenic tyrosine kinases target Dok-1 for ubiquitin-mediated proteasomal degradation to promote cell transformation.

Authors:  Justyna A Janas; Linda Van Aelst
Journal:  Mol Cell Biol       Date:  2011-05-02       Impact factor: 4.272

4.  Similarity of gene expression patterns in human alveolar macrophages in response to Pseudomonas aeruginosa and Burkholderia cepacia.

Authors:  Stefan Worgall; Adriana Heguy; Karsta Luettich; Timothy P O'Connor; Ben-Gary Harvey; Luis E N Quadri; Ronald G Crystal
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

5.  SH2-containing inositol 5'-phosphatase inhibits transformation of Abelson murine leukemia virus.

Authors:  Shawn P Fessler; Naomi Rosenberg; Linda B Baughn
Journal:  J Virol       Date:  2011-06-22       Impact factor: 5.103

6.  Comprehensive analysis of DOK family genes expression, immune characteristics, and drug sensitivity in human tumors.

Authors:  Yongjun Guan; Man Li; Zhendong Qiu; Junhui Xu; Yichao Zhang; Ning Hu; Xuanzhe Zhang; Wenyi Guo; Jingping Yuan; Qiao Shi; Weixing Wang
Journal:  J Adv Res       Date:  2021-06-12       Impact factor: 10.479

7.  BRK targets Dok1 for ubiquitin-mediated proteasomal degradation to promote cell proliferation and migration.

Authors:  Sayem Miah; Raghuveera Kumar Goel; Chenlu Dai; Natasha Kalra; Erika Beaton-Brown; Edward T Bagu; Keith Bonham; Kiven E Lukong
Journal:  PLoS One       Date:  2014-02-11       Impact factor: 3.240

8.  Phosphofructokinases Axis Controls Glucose-Dependent mTORC1 Activation Driven by E2F1.

Authors:  Eugènia Almacellas; Joffrey Pelletier; Anna Manzano; Antonio Gentilella; Santiago Ambrosio; Caroline Mauvezin; Albert Tauler
Journal:  iScience       Date:  2019-10-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.